Pfizer-BioNTech's COVID-19 Vaccine Giving 70% Protection Against Omicron, South Africa's Private Health Insurer Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Pfizer (PFE) Announces FDA Approval of XELJANZ for the Treatment of Active Ankylosing Spondylitis
December 14, 2021 4:08 PM ESTPfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate... More
UBS Upgrades Pfizer (PFE) to Buy, Downgrades Merck (MRK) to Neutral
December 13, 2021 9:51 AM ESTUBS analyst Colin Bristow downgraded shares of Merck to Neutral (NYSE: MRK) on the lack of evident catalysts and the lack of visibility around key growth drivers.
The analyst also lowered the price target to $76.00 per share from the prior $98.00 as two key growth drivers - islatravir for HIV, molnupiravir for COVID - facilitated negative updates recentl
molnup's hospitalization/death relative risk reduction dropped from 48% (at interim) to ~30% (all evaluable patients) and... More
Pfizer (PFE) to Buy Arena Pharmaceuticals (ARNA) in a $6.7 Billion Deal, Pays a 100% Premium; Seen as the First of Many Acquisitions
December 13, 2021 6:41 AM ESTPfizer (NYSE: PFE) shares are up 2% in pre-open Monday after the company announced a deal to buy Arena Pharmaceuticals (Nasdaq: ARNA) in a $6.7 billion deal.
Pfizer will pay $100 per share in an all-cash transaction, which is a 100% premium compared to Fridays closing price of $49.94 per share.
Arena is a clinical-stage... More
